Systematic review of purine analog treatment for chronic lymphocytic leukemia: Lessons for future trials

Haematologica

Volumn 97, Issue 3, 2012, Pages 428-436

  Richards, Sue ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

CLL; Combination therapy; Cyclophosphamide; Purine analog; Review

Indexed keywords

ALKYLATING AGENT; BETA 2 MICROGLOBULIN; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUDARABINE; PREDNISOLONE; PURINE DERIVATIVE; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL RESEARCH; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; META ANALYSIS (TOPIC); OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PURINES; TREATMENT OUTCOME;

EID: 84857762597     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.053512     Document Type: Article

References (28)

1. CLL Trialists' Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst. 1999;91(10):861-8.
2. Steurer M, Pall G, Richards S, Schwarzer G, Bohlius J, Greil R. Purine antagonists for chronic lymphocytic leukaemia. Cochrane Database Syst Rev. 2006;3:CD004270.
3. Steurer M, Pall G, Richards S, Schwarzer G, Bohlius J, Greil R. Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis. Cancer Treat Rev. 2006;32(5):377-89.
4. Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desablens B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 2001;98(8):2319-25.
5. Johnson S, Smith AG, Loffler H, Osby E, Juliusson G, Emmerich B, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet. 1996;347(9013):1432-8.
6. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343(24):1750-7.
7. Jaksic B, Brugiatelli M, Suciu S, Beaumelou E, Wijremans PW, Delmer A, et al. Fludarabine vs. high dose chlorambucil in advanced B-cell chronic lymphocytic leukemia (B-CLL): results of EORTC phase-II randomized trial after 4 years of median follow-up [Abstract]. Blood. 2000;96(11): 758a, A3280.
8. Spriano M, Chiurazzi F, Liso V, Mazza P, Molica S, Gobbi M. Multicentre prospective randomized trial of fludarabine versus chlorambucil and prednisone in previously untreated patients with active B-CLL: final report [Abstract]. Hematol Cell Ther. 2000;32(1):93, P086.
9. Robak T, Blonski JZ, Kasznicki M, Blasinska Morawiec M, Krykowski E, Dmoszynska A, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood. 2000;96(8):2723-9.
10. Robak T, Blonski JZ, Kasznicki M, Gora-Tybor J, Dmoszynska A, Wojtaszko M, et al. Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1). Med Sci Monit. 2005;11(10):PI71-9.
11. Karlsson K, Strömberg M, Jönsson V, Mulligan S, Liliemark J, Juliusson G, et al. Improved response duration from first-line treatment with cladribine (CdA), as compared to fludarabine (F) or high-dose intermittent chlorambucil (Chl) for first-line treatment of symptomatic chronic lymphocytic leukemia (CLL). First results from the International Randomized Phase III Trial [Abstract]. Leuk Lymphoma. 2007;48(Suppl1):S167-S168, P 5.14.
12. Rummel MJ, Stilgenbauer S, Gamm H, Rost A, Hartmut D, Hoelzer D, et al. Fludarabine versus fludarabine plus epirubicin in the treatment of chronic lymphocytic leukemia-final results of a German randomized phase-III study [Abstract]. Blood. 2005;106 (11):A2123.
13. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJS, Bezares RF, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007;370 (9583):230-9.
14. Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup trial E2997. J Clin Oncol 2007;25(7):793-8.
15. Robak T, Blonski JZ, Gora-Tybor J, Jamroziak K, Dwilewicz-Trojaczek J, Tomaszewska A, et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood. 2006;108(2):473-9.
16. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107(3):885-91.
17. Eichhorst BF, Busch R, Stilgenbauer S, Stauch M, Bergmann MA, Ritgen M, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood. 2009;114(16):3382-91.
18. Ivanaj A, Xhumari PXH, Pulluqi PP, Ruka IR. Comparison of fludarabine (FDB) vs CVP in untreated chronic lymphocytic leukemia (CLL). Preliminary results of a randomized clinical trial [Abstract]. Haematologica. 2003;4(Suppl 2):300, A1024.
19. Abdelhamid TH, Al-Lahloby N, Kamel A, Elsharkawy N, Zaher A, Francis N. Fludarabine and cyclophosphamide (FC) versus cyclophosphamide, vincristine and prednisone (CVP) as first line treatment in chronic lymphocytic leukaemia (CLL) [Abstract]. Haematologica. 2006;91(Suppl1):290-291, A0791.
20. Robak T, Jamroziak K, Gora-Tybor J, Stella-Holowiecka B, Konopka L, Ceglarek B, et al. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol. 2010;28(11):1863-9.
21. Pulluqi PP, Ruka RI, Xhumari P, Mitre MA, Caja CT. Factors that influence remission and survival in previously treated CLL patients [Abstract]. Haematologica. 2002; A0894.
22. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood. 1989;74(1):19-25.
23. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008; 358(3):252-60.
24. Montserrat E. Treatment options in chronic lymphocytic leukemia. Hematol J 2004;5 (Suppl 1):S2-9.
25. Rai K, Peterson BL, Appelbaum FR, Tallman MS, Belch A, Morrison VA, et al. Long-term survival analysis of the North American Intergroup Study C9011 comparing fludarabine (F) and Chlorambucil (C) in previously untreated patients with chronic lymphocytic leukemia (CLL). Blood. 2009;114: A536.
26. Schulz KF, Altman DG, Moher D; for the CONSORT Group. CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials. PLoS Med. 2010;7(3):e1000251. doi:10.1371/journal.pmed.1000251.
27. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111 (12):5446-56.
28. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-74.